RECURRENT FALLOPIAN TUBE CARCINOMA

This study is testing whether combining three existing cancer drugs works better than current options for women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned or stopped responding to platinum chemotherapy. The trial will enroll 38 participa…

This early-stage study is testing a combination of two drugs, niraparib (a pill) and copanlisib (an IV infusion), for women whose ovarian, endometrial, or related cancers have returned after prior treatment. The main goals are to find the safest dose of this combination and to le…

This large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …

This study is testing if a two-drug combination can stop ovarian, fallopian tube, or primary peritoneal cancer from getting worse after it has come back. The treatment pairs an immunotherapy drug (pembrolizumab) that helps the immune system fight cancer with a chemotherapy drug (…

This study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combi…

This study is testing which combination of three drugs works best to control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. It involves 444 patients and compares a standard two-drug combo agains…

This large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…

This early-stage study is testing the safety and best dose of a new oral drug, MLN0128, when given with the existing cancer drug bevacizumab. It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have stopped responding to standa…

This study is testing whether a combination of two oral drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemoth…

This early-stage study is testing whether adding an experimental drug called berzosertib (M6620) to standard chemotherapy (carboplatin and gemcitabine) is safe and might work better for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned. The main goal …

This early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…

This early-stage study is testing whether washing the abdomen with heated chemotherapy during cancer-removal surgery is safe and feasible for patients with advanced or recurrent ovarian, fallopian tube, uterine, or peritoneal cancers. The goal is to see if this approach, sometime…

This large, late-stage trial is testing which combination of chemotherapy drugs works best for women with a specific type of ovarian or fallopian tube cancer (mucinous adenocarcinoma). It compares two standard drug pairs, with or without an added drug (bevacizumab) that blocks tu…

This study is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Doctors are using a specially engineered measles virus, which is carried directly to the cancer by the patient's own fat-derived stem cells, …

This early-stage trial is testing the safety and best doses of two different combinations of oral medications for people with recurrent endometrial, ovarian, or triple-negative breast cancer. The study combines an existing drug (olaparib) with one of two newer drugs (AZD2014 or A…

This study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…

This study is testing if a two-drug combination works better than a single drug to control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. It compares a targeted pill (olaparib) alone to the pill plus an immunotherapy drug (tr…

This study is testing whether two different drug combinations can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has continued to grow despite previous treatment with a specific type of targeted therapy called a PARP inhibitor. It will enroll ab…

This study is testing if adding a new drug called M6620 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum drugs. The main goal is…